Skip to main content

Powered by curiosity. Inspired by people.

We want to do more for people living with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases and their families. We want to partner with individuals and companies who share our passion for bringing innovative ideas and solutions to the neurodegenerative disease community. In working together, we can leverage our strengths, assets and relationships to make an impact on the lives of those who need it most.

Partner with Amylyx

True collaboration is the fastest way forward. If you are a researcher or biotech company looking for a partner in your mission to improve the lives of those living with neurodegenerative diseases, we would love to hear from you. Our collective success is the result of unique approaches, collaboration across the ALS community, and above all, a relentless commitment to helping people with neurodegenerative diseases. In less than a decade of collaborative effort, we are proud to have demonstrated that our oral drug candidate AMX0035 (sodium phenylbutyrate/taurursodiol) provides clinical benefit in ALS.

Interested? Let’s talk.

We’d love to hear about your work and to consider the various ways in which we partner together. Submit your information in the link below and a member of our team will reach out for further discussion.

Our Pipeline

In designing our trials, we rely on the input of clinical leaders, advocacy groups, and the neurodegenerative disease community. This collaborative approach has kept people living with neurodegenerative diseases at the center of everything we do and is something we will continue in future trials. Learn more about our clinical trials and progress to date.

Pipeline Graphic

Featured Publications

Muscle & Nerve

October 2020

Data from the CENTAUR trial published in Muscle & Nerve demonstrates that the administration of AMX0035 results in longer survival for people living with ALS compared to placebo.


The New England Journal of Medicine

September 2020

As published in the New England Journal of Medicine (NEJM), pivotal the CENTAUR trial met its prespecified primary outcome, showing a clinically meaningful and statistically significant benefit on the Revised ALS Functional Rating Scale (ALSFRS-R) — representing a major milestone for the ALS community. Participants experienced similar rates of adverse events in the AMX0035 and placebo groups; however GI events occurred with greater frequency (≥2%) in the AMX0035 group.